New reports from LSI are forecasting the impact of Coronavirus on global medical devices & diagnostics markets and the impact to suppliers & the competitive landscape.
HUNTINGTON BEACH, Calif.–(BUSINESS WIRE)–#lsintelligence–Leading medtech market research firms Life Science Intelligence (LSI) and Health Research International (HRI) have released new data predicting massive growth in the global drug delivery markets in 2020 largely driven by the Coronavirus pandemic.
Major suppliers that are likely to see a boost in 2020 revenues within their drug delivery product lines include:
In addition to coverage of drug delivery markets, the new market intel platform COVID-19 Impact Tracker includes forecasts for 2019 through 2024 for the following medical device & diagnostic segments:
To learn more about this service, visit: https://www.lifesciencemarketresearch.com/covid-19-impact-tracker
About Life Science Intelligence (LSI) and Health Research International (HRI)
LSI and HRI have been tracking and forecasting Global MD&D Markets for 3 decades and are sought after by leading medical device, diagnostic and financial services firms for an independent and realistic assessment of market sizes and trends across the major medical technology segments. These research firms are strategic partners and collaborate on research projects and industry reports. HRI is a boutique market research and custom consulting firm with more than 40 years of experience analyzing and forecasting the full array medical devices & diagnostics markets. LSI is a medical technology market intelligence & consulting company with over 25 years of experience. Together LSI & HRI help medtech executives make informed strategic decisions faster.
Contacts
Maricela Almonte
Life Science Intelligence
714 847 3540 Tel
malmonte@ls-intel.com
Chicago, Illinois--(Newsfile Corp. - February 5, 2026) - HPN Holdings, Inc. (OTCID: KICK) ("HPN" or…
In the newly-released educational guide What Is Rapé?, Sacred Connection covers essential topics around Rapé…
Accelerating platform-driven clinical innovation across vascular, neurovascular, and cardiovascular applications through a centralized Bionanomatrix™ IP…
Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over…
SAN JOSE, CA / ACCESS Newswire / February 5, 2026 / VSEE Health, Inc. (NASDAQ:VSEE),…
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA…